203 related articles for article (PubMed ID: 15952914)
1. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
Hurvitz SA; Timmerman JM
Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
4. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
Reinis M
Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
[TBL] [Abstract][Full Text] [Related]
5. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
McCormick AA; Reddy S; Reinl SJ; Cameron TI; Czerwinkski DK; Vojdani F; Hanley KM; Garger SJ; White EL; Novak J; Barrett J; Holtz RB; Tusé D; Levy R
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10131-6. PubMed ID: 18645180
[TBL] [Abstract][Full Text] [Related]
6. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
Schumacher K
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R10-3. PubMed ID: 11768618
[No Abstract] [Full Text] [Related]
7. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
8. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
Lee ST; Jiang YF; Park KU; Woo AF; Neelapu SS
Expert Opin Biol Ther; 2007 Jan; 7(1):113-22. PubMed ID: 17150023
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
10. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
Freedman A; Neelapu SS; Nichols C; Robertson MJ; Djulbegovic B; Winter JN; Bender JF; Gold DP; Ghalie RG; Stewart ME; Esquibel V; Hamlin P
J Clin Oncol; 2009 Jun; 27(18):3036-43. PubMed ID: 19414675
[TBL] [Abstract][Full Text] [Related]
13. Translational development of active immunotherapy for hematologic malignancies.
Kwak LW
Semin Oncol; 2003 Jun; 30(3 Suppl 8):17-22. PubMed ID: 12881808
[TBL] [Abstract][Full Text] [Related]
14. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
Reinis M
Curr Opin Mol Ther; 2008 Oct; 10(5):526-34. PubMed ID: 18830928
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
Timmerman JM; Vose JM; Czerwinski DK; Weng WK; Ingolia D; Mayo M; Denney DW; Levy R
Leuk Lymphoma; 2009 Jan; 50(1):37-46. PubMed ID: 19125383
[TBL] [Abstract][Full Text] [Related]
16. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
Flowers CR
Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
[TBL] [Abstract][Full Text] [Related]
18. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
19. Vaccination as immunotherapy for B cell lymphoma.
Schultze JL
Hematol Oncol; 1997 Aug; 15(3):129-39. PubMed ID: 9600112
[TBL] [Abstract][Full Text] [Related]
20. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
